Scoop

Executive Summary

Scoop is a preclinical biotechnology company pioneering a novel molecular glue-based protein degradation platform to target historically undruggable proteins driving oncology and neurodegenerative diseases. Unlike traditional degraders, Scoop's molecular glues induce proximity between E3 ligases and disease-causing proteins, enabling selective ubiquitination and proteasomal degradation. This approach expands the druggable proteome by targeting proteins lacking conventional binding pockets, including transcription factors, scaffolding proteins, and aggregation-prone species. Founded in 2025 and affiliated with Y Combinator, Scoop is capitalizing on the rapidly growing interest in targeted protein degradation, a modality validated by recent approvals in oncology. The company's early research has demonstrated high specificity and potent degradation in cellular models, positioning it to address high-unmet-need indications such as KRAS-mutant cancers and tauopathies. With a lean team of fewer than 50 employees, Scoop is advancing its lead candidates toward IND-enabling studies, focusing on lead optimization, pharmacokinetics, and preliminary toxicity profiling. The platform's versatility also suggests potential for rapid expansion into other disease areas. As a private, pre-revenue entity, Scoop's near-term value hinges on preclinical proof-of-concept data and its ability to attract strategic partnerships or Series A financing. The company's innovative technology, combined with the proven commercial success of degradation therapies, underpins its potential to become a key player in the next wave of precision therapeutics.

Upcoming Catalysts (preview)

• Q4 2026Lead candidate nomination for first oncology target60% success
• Q3 2026Series A funding round50% success
• Q2 2027Preclinical data presentation at major conference (e.g., AACR, AD/PD)70% success